ICOSAVAX, INC. Research and Development Expense
ICOSAVAX, INC. reported Research and Development Expense of $16.67 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-11-14
- ICOSAVAX, INC. research and development expense for the quarter ending 2023-09-30 was $16.67M, a 7.65% increase year-over-year.
- ICOSAVAX, INC. research and development expense for the quarter ending 2023-06-30 was $19.83M, a 25.32% increase year-over-year.
- ICOSAVAX, INC. research and development expense for the quarter ending 2023-03-31 was $17.36M, a 3.10% decline year-over-year.
- ICOSAVAX, INC. research and development expense for the quarter ending 2022-12-31 was $16.19M, a 15.15% increase year-over-year.
- ICOSAVAX, INC. research and development expense for fiscal 2022 was $65.41M, a 68.69% increase from fiscal 2021.
- ICOSAVAX, INC. research and development expense for fiscal 2021 was $38.78M, a 119.48% increase from fiscal 2020.
- ICOSAVAX, INC. research and development expense for fiscal 2020 was $17.67M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $16.67M 10-Q · filed 2023-11-14 | $36.49M derived: sum of 2 quarters · filed 2023-11-14 | $53.85M 10-Q · filed 2023-11-14 | $70.04M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | $19.83M 10-Q · filed 2023-08-14 | $37.18M 10-Q · filed 2023-08-14 | $53.38M derived: sum of 3 quarters · filed 2023-08-14 | $68.86M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-03-31 | $17.36M 10-Q · filed 2023-05-10 | $33.55M derived: sum of 2 quarters · filed 2023-05-10 | $49.03M derived: sum of 3 quarters · filed 2023-11-14 | $64.85M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | $16.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $31.68M derived: sum of 2 quarters · filed 2023-11-14 | $47.50M derived: sum of 3 quarters · filed 2023-11-14 | $65.41M 10-K · filed 2023-03-30 |
| 2022-09-30 | $15.48M 10-Q · filed 2023-11-14 | $31.30M derived: sum of 2 quarters · filed 2023-11-14 | $49.22M 10-Q · filed 2023-11-14 | $63.28M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $15.82M 10-Q · filed 2023-08-14 | $33.73M 10-Q · filed 2023-08-14 | $47.80M derived: sum of 3 quarters · filed 2023-08-14 | $58.68M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $17.91M 10-Q · filed 2023-05-10 | $31.98M derived: sum of 2 quarters · filed 2023-05-10 | $42.86M derived: sum of 3 quarters · filed 2023-05-10 | $51.14M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $14.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $24.95M derived: sum of 2 quarters · filed 2023-03-30 | $33.22M derived: sum of 3 quarters · filed 2023-03-30 | $38.78M 10-K · filed 2023-03-30 |
| 2021-09-30 | $10.88M 10-Q · filed 2022-11-14 | $19.16M derived: sum of 2 quarters · filed 2022-11-14 | $24.71M 10-Q · filed 2022-11-14 | $30.04M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $8.28M 10-Q · filed 2022-08-15 | $13.83M 10-Q · filed 2022-08-15 | $19.16M derived: sum of 3 quarters · filed 2022-08-15 | $23.91M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $5.55M 10-Q · filed 2022-05-16 | $10.88M derived: sum of 2 quarters · filed 2022-05-16 | $15.63M derived: sum of 3 quarters · filed 2022-05-16 | $20.30M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $5.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $10.08M derived: sum of 2 quarters · filed 2022-03-30 | $14.75M derived: sum of 3 quarters · filed 2022-03-30 | $17.67M 10-K · filed 2022-03-30 |
| 2020-09-30 | $4.75M 10-Q · filed 2021-11-15 | $9.42M derived: sum of 2 quarters · filed 2021-11-15 | $12.34M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $4.67M 10-Q · filed 2021-09-13 | $7.59M 10-Q · filed 2021-09-13 |